ABL Bio Seeks Diverse Partnerships at BIO USA

ABL Bio, a company specializing in bispecific antibodies, announced on June 16 that it will participate in the 'BIO International Convention (BIO USA) 2026,' which will be held in San Diego, United States, from June 22 to 25 (local time), in order to seek opportunities to expand its global partnerships.

In addition, CEO Sang Hoon Lee will join the panel for the 'Korea Rising: Don't Be Late to Asia's Next Innovation Hub' session on June 23 (local time), where he will discuss the competitiveness of the Korean bio industry and opportunities for global collaboration.

BIO USA is the world’s largest bio event, bringing together pharmaceutical and biotech professionals from around the globe for a wide range of discussions. During the event, ABL Bio plans to meet with various global pharmaceutical and biotech companies to discuss collaboration opportunities related to its blood-brain barrier (BBB) shuttle platform, Grabody-B, as well as its 4-1BB-based bispecific antibody immuno-oncology drug candidates.

In particular, Grabody-B is expected to attract strong interest at this event, given that the platform proved its technological value and competitiveness in the global market last year by sequentially signing technology transfer agreements with GSK and Eli Lilly. In February of this year, research results were announced confirming that when small interfering RNA (siRNA) is combined with Grabody-B, it enables delivery to various tissues, including several regions of the brain such as the cerebellum, as well as muscles, heart, and lungs. As a result, corporate interest in related data is expanding.

ABL Bio also plans to share clinical data from immuno-oncology therapies utilizing its 4-1BB-based bispecific antibody platform Grabody-T and discuss related business development opportunities. Among its Grabody-T-based pipeline, the fastest-developing candidate is Givastomig (ABL111), which is being evaluated in combination with chemotherapy (FOLFOX) and the PD-1 inhibitor nivolumab as a first-line treatment for gastric cancer patients in a Phase 2 clinical trial. The company plans to enter Phase 3 clinical trials for accelerated approval in the fourth quarter of this year. Another Grabody-T-based bispecific antibody, Ragistomig (ABL503), will see its clinical trials expanded from monotherapy to combination therapies.

Additionally, ABL Bio plans to explore the latest technologies that support the development of next-generation bispecific antibody ADCs, including dual payload ADCs, and monitor global trends in new drug development among leading companies.

CEO Sang Hoon Lee of ABL Bio stated, "At this year's BIO USA, we will actively seek a variety of business development opportunities, including the establishment of long-term partnerships, while broadly discussing our strategy to expand clinical development. As we continue to accumulate both preclinical and clinical data on our technologies through sustained research and development, we are seeing increasing interest not only from companies we have been in ongoing discussions with, but also from new partners. We will do our utmost to achieve meaningful results at this event."

This content was produced with the assistance of AI translation services.